An observational study in Systolic Hypertension, Pregnancy Related and Diastolic Hypertension, sponsored by Marshall University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Marshall University · Observational
The purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.
When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital, she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual protocol. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). The medication to be given to each subject will be based on their hemodynamics. Specifically, nifedipine will be given for a mean arterial pressure >100 and a beta blocker will be given for a cardiac output >8 l/min. The patients will be asked to return in one week for repeat ICG measurement.
35 studies on the registry are indexed under Isolated Systolic Hypertension; 8 are open to participants now.
Browse Isolated Systolic Hypertension studies →Marshall University is the lead sponsor of 20 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients presenting to the Maternal Hypertension Center at Cabell Huntington Hospital. Consent will be obtained prior to enrollment. Patient age range will be from age 18 to approximately 45.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Beta blocker (labetalol or atenolol) will be given for a cardiac output \>8 l/min.
Drug: Labetalol · Drug: Atenolol
Nifedipine will be given for a mean arterial pressure \>100.
Drug: Nifedipine
Beta blocker
Also known as: Normodyne, Trandate
Beta blocker
Also known as: Tenormin
Calcium channel blocker
Also known as: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL
Systolic blood pressure
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Diastolic blood pressure
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Mean arterial pressure
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Heart rate
Measured in beats per minute
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Cardiac output
Measured in liters per minute
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Systemic vascular resistance
Measured by dynes · sec/cm\^-5
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Dec 2025, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Isolated Systolic Hypertension →
Marshall University